雇用契約第4条に基づき(「雇用契約書”) between you and Black Diamond Therapeutics, Inc., a Delaware corporation (the “会社”), this letter will serve as notice of termination of your employment, effective October 7, 2024 (the “解雇日”). Your employment is being terminated pursuant to Section 3(d) of the Employment Agreement (termination by the Company without Cause).
This letter also sets forth the terms of a Separation Agreement and Release (the “契約”), as that term is defined in the Employment Agreement. In the interest of clarity, the following terms and conditions shall apply regardless of whether you elect to accept or reject the Agreement:
•Company との従業員機密保持、譲渡、顧客獲得禁止および競争禁止協定に基づくあなたの義務(以下、「Restrictive Covenants Agreement”) remain in full force; provided, however, the Company hereby agrees to waive the post-employment noncompetition restriction contained in Section 8(c) of the Restrictive Covenants Agreement. The remaining post-termination obligations in the Restrictive Covenants Agreement and any other confidentiality, assignment of inventions, and restrictive covenants agreement that you entered into with the Company or its affiliates or any other policies and agreements with continuing obligations (collectively, the “続行義務。 あなたは、会社の取締役会との契約書、およびあなたと締結した他の同様の契約書に基づき、会社グループに対する継続的な義務を確認し、再確認します。これらの契約と義務は、引き離し日(または適用される場合は早期引き離し日)以降も、その条件に従って完全に有効であり続けます。”) will survive in accordance with their terms.
In addition to the above described non-contingent terms, if you enter into and comply with the below Agreement, you will be entitled to the severance pay and other benefits described in Section 2. The remainder of this letter sets forth the Agreement.
With those understandings, you and the Company agree as follows:
Black Diamond Therapeutics, Inc. | One Main Street | 14階 Floor | Cambridge, MA 02142
(b)Subject to your copayment of premium amounts at the applicable active employees’ rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider, the COBRA provider or to you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Separation Date; (B) your eligibility for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of your continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.
(c)Immediately following the Separation Date, you will become an advisor to the Company and be reasonably available to provide advisory services to the Company on an as-needed basis as requested by the Chief Executive Officer of the Company (the “Advisory Services”) for three (3) months from the Separation Date (the “Advisory Period”). The terms and conditions of your advisory relationship with the Company are set forth in the advisory agreement attached hereto as 同意書. You will be reimbursed for all reasonable expenses that you incur in performing any requested Advisory Services, subject to you providing documentation of such expenses and